NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers

Apr 23, 2007, 01:00 ET from Rosetta Genomics Ltd

    REHOVOT, Israel and NEW YORK, New York, April 23 /PRNewswire-FirstCall/
 -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that it has
 partnered with NYU Medical Center with the aim of developing a line of
 early detection diagnostic products for lung, and Mesothelioma cancers.
     The early detection test will mainly target over 45 million Americans
 who are at an increased risk of lung cancer due to smoking, as well as
 those who have been exposed to asbestos fibers. The test will utilize
 Rosetta Genomics' proprietary protocol to extract microRNAs from a simple
 blood draw.
     "A test that will be able to detect cancer at an early stage using a
 simple blood draw will have far reaching implications on the fight against
 cancer," noted Dr. Harvey Pass, Professor and Chief, Division of Thoracic
 Surgery and Thoracic Oncology at NYU Medical Center. "MicroRNAs have been
 shown to hold great potential as effective biomarkers for various cancers,
 and I believe that NYU Medical Center's vast experience with lung cancer
 and Mesothelioma, coupled with Rosetta Genomics' expertise in the microRNA
 field, will allow us to successfully advance this much needed test
     About Mesothelioma
     Mesothelioma is a form of cancer that is almost always caused by
 previous exposure to asbestos. In this disease, malignant cells develop in
 the mesothelium, a protective lining that covers most of the body's
 internal organs. Most people who develop mesothelioma have worked on jobs
 where they inhaled asbestos particles, or have been exposed to high levels
 of asbestos fibers.
     About Lung Cancer
     Lung Cancer is the leading cause of death for both men and women.
 According to the American Cancer Society (ACS), in 2007 there will be about
 213,000 new cases of lung cancer, and approximately 160,000 deaths. Average
 five-year survival rates for patients diagnosed with lung cancer are less
 than 15%. Five year survival rates for patients with advanced stage IV lung
 cancer are only about 5%. The population at highest risk for lung cancer
 includes approximately 5 million men and women between the ages of 50 and
 69 who are current or former smokers.
     About microRNAs
     MicroRNAs (miRNAs) are a recently discovered, naturally occurring form
 of RNAi. These small RNAs act as protein regulators and have the potential
 to form the basis for a new class of diagnostics and therapeutics. Since
 many diseases are caused by the abnormal activity of proteins, the ability
 to selectively regulate protein activity through microRNAs could provide
 the means to treat a wide range of human diseases. In addition, microRNAs
 have been shown to have different expression levels in certain diseased
 versus normal tissues. As a result, these differences potentially provide
 for a novel diagnostic strategy for many diseases. MicroRNAs are thought to
 play a key role in the differentiation of cells into specific cell types
 performing various functions in the body.
     About NYU Medical Center
     One of the world's premier academic medical institutions for more than
 155 years, NYU Medical Center continues to be a leader in patient care,
 physician education and scientific research. NYU Medical Center is
 internationally renowned for excellence in areas such as cardiovascular
 disease, pediatrics, skin care, neurosurgery, urology, cancer care,
 rehabilitation, plastic surgery, minimally invasive surgery, transplant
 surgery, infertility, women's health and day surgery.
     About Rosetta Genomics
     Rosetta Genomics (Nasdaq:   ROSG) is a leader in the development of
 microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
 integrative research platform combining bioinformatics and state-of-the-art
 laboratory processes has led to the discovery of hundreds of biologically
 validated novel human microRNAs. Building on its strong IP position and
 strategic alliances with leading biotechnology companies, Rosetta Genomics
 is working to develop a full range of diagnostic and therapeutic products
 based on microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785
     Forward-Looking Statement Disclaimer
     Various statements in this release concerning Rosetta's future
 expectations, plans and prospects, including without limitation, statements
 relating to our ability to successfully develop early detection diagnostic
 products for lung cancer and Mesothelioma in collaboration with NYU Medical
 Center, the role of miRNAs in human physiology and disease, and the
 potential of microRNAs in the diagnosis and treatment of disease,
 constitute forward-looking statements for the purposes of the safe harbor
 provisions under The Private Securities Litigation Reform Act of 1995.
 Actual results may differ materially from those indicated by these
 forward-looking statements as a result of various important factors,
 including risks related to: Rosetta's approach to discover and develop
 novel diagnostics products, which is unproven and may never lead to
 marketable products; Rosetta's ability to fund and the results of further
 pre-clinical and clinical trials; obtaining, maintaining and protecting
 intellectual property utilized by Rosetta's products; Rosetta's ability to
 enforce its patents against infringers and to defend its patent portfolio
 against challenges from third parties; Rosetta's ability to obtain
 additional funding to support its business activities; Rosetta's dependence
 on third parties for development, manufacture, marketing, sales, and
 distribution of products; the successful development of Rosetta's product
 candidates, all of which are in early stages of development; obtaining
 regulatory approval for products; competition from others using technology
 similar to Rosetta's and others developing products for similar uses;
 Rosetta's dependence on collaborators; and Rosetta's short operating
 history; as well as those risks more fully discussed in the "Risk Factors"
 section of Rosetta's most recent Registration Statement on Form F-1 on file
 with the Securities and Exchange Commission. In addition, any
 forward-looking statements represent Rosetta's views only as of today and
 should not be relied upon as representing its views as of any subsequent
 date. Rosetta does not assume any obligation to update any forward-looking
 statements unless required by law.

SOURCE Rosetta Genomics Ltd